Compare AUUD & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUUD | INM |
|---|---|---|
| Founded | 2012 | 1981 |
| Country | United States | Canada |
| Employees | 6 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.7M |
| IPO Year | N/A | 2020 |
| Metric | AUUD | INM |
|---|---|---|
| Price | $0.80 | $0.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 77.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,942,633.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.50 |
| 52 Week Low | $0.21 | $0.73 |
| 52 Week High | $7.29 | $7.98 |
| Indicator | AUUD | INM |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 47.32 |
| Support Level | $0.66 | $0.73 |
| Resistance Level | $1.20 | $1.40 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 24.26 | 66.98 |
Auddia Inc is a United States-based company. It operates through its proprietary AI platform for audio and is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. The group Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Its flagship audio superapp, called faidr, delivers multiple industry firsts, including: Ad-free listening on any AM/FM radio station, Content skipping across any AM/FM station, One-touch skipping of entire podcast ad breaks, and Integrated artist discovery experiences.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.